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Abstract TP53 is conventionally thought to prevent cancer formation and progression to
metastasis, while mutant TP53 has transforming activities. However, in the clinic, TP53 mutation
status does not accurately predict cancer progression. Here we report, based on clinical analysis
corroborated with experimental data, that the p53 isoform D133p53b promotes cancer cell
invasion, regardless of TP53 mutation status. D133p53b increases risk of cancer recurrence and
death in breast cancer patients. Furthermore D133p53b is critical to define invasiveness in a panel
of breast and colon cell lines, expressing WT or mutant TP53. Endogenous mutant D133p53b
depletion prevents invasiveness without affecting mutant full-length p53 protein expression.
Mechanistically WT and mutant D133p53b induces EMT. Our findings provide explanations to 2
long-lasting and important clinical conundrums: how WT TP53 can promote cancer cell invasion and
reciprocally why mutant TP53 gene does not systematically induce cancer progression.
DOI: 10.7554/eLife.14734.001
Introduction
Cancer is driven by somatically acquired point mutations and chromosomal rearrangements, that are
thought to accumulate gradually over time. Recent whole cancer genome sequencing studies have
conclusively established that the tumor suppressor gene, TP53, is the most frequently mutated gene
in a wide range of cancer types. In tumors expressing wild-type (WT) TP53 gene, numerous experi-
mental and clinical data have shown that viruses or cellular oncogene proteins target the p53 path-
way, promoting abnormal cell proliferation. Altogether these data strongly suggest that defects in
TP53 tumor suppressor activity are a compulsory step to cancer formation. In addition, ample data
have also demonstrated that TP53 gene, whether WT or mutant, has a paramount biological and
clinical role in response to cancer treatment (Brosh and Rotter, 2009; Do et al., 2012;
Jackson et al., 2012; Muller et al., 2009).
We previously reported that the human TP53 gene expresses at least twelve p53 isoforms
through alternative splicing of intron-2 (D40) and intron-9 (a, b, g), initiation of transcription in intron-
4 (D133) and alternative initiation of translation at codon 40 (D40) and codon 160 (D160). This leads
to the expression of p53 (a, b, g), D40p53 (a, b, g ), D133p53 (a, b, g ) and D160p53 (a, b, g ) protein
Gadea et al. eLife 2016;5:e14734. DOI: 10.7554/eLife.14734 1 of 26
RESEARCH ARTICLE
isoforms that contain different transactivation domain, oligomerisation domains and regulatory
domains (for review Joruiz and Bourdon, 2016).
All animal models (zebrafish, drosophila and mouse) of p53 isoforms and experimental data in
human cells of diverse tissue origins have consistently shown that p53 isoforms regulate cell cycle
progression, programmed cell death, replicative senescence, viral replication, cell differentiation and
angiogenesis. Several clinical studies reported that abnormal expressions of p53 isoforms are found
in a wide range of human cancers including breast and colon cancers and that p53 isoforms are asso-
ciated with cancer prognosis (Joruiz and Bourdon, 2016). However, it is not known whether they
are just markers or play an active role in cancer formation and progression. Recently, we reported
that D133p53b promotes cancer stem cell potential and metastasis formation in a xenograft mouse
model (Arsic et al., 2015). However, its physiopathological role, its molecular mechanism, its associ-
ation with cancer progression and the effect of TP53 mutations on its activities have never been
investigated.
To date, it is currently thought that all the tumor suppressor activities associated with TP53 or the
oncogenic activities associated with mutant TP53 gene expression are implemented by the canonical
full-length p53 protein (also named TAp53a or p53a). It is well established that TAp53a , is a tran-
scription factor rapidly activated to restore and maintain cell integrity in response to alteration of
cell homeostasis, while most TAp53a missense mutants have compromised tumor suppressor activi-
ties and have acquired transforming activities.
Compelling evidence indicates that WT TAp53a protein, plays a pre-eminent role in preventing
human cancer formation and progression to metastasis. In particular, WT TAp53a protein prevents
cell migration and invasion which are the main traits of Epithelial to Mesenchymal Transition (EMT),
which itself involves global genome reprogramming that drives cancer progression to metastasis
(McDonald et al., 2011; Suva et al., 2013). Conversely, most TAp53a missense mutant proteins
eLife digest Most cancers are caused by a build-up of mutations that are acquired throughout
life. One gene in particular, called TP53, is the most commonly mutated gene in many types of
human cancers. This suggests that TP53 mutations play an important role in cancer development.
It is widely considered that the TP53 gene normally stops tumors from forming, while mutant
forms of the gene somehow promote cancer growth. Evidence from patients with cancer has shown,
however, that the relationship between TP53 mutations and cancer is not that simple. Some very
aggressive cancers that resist treatment and spread have a normal TP53 gene. Some cancers with a
mutated gene do not spread and respond well to cancer treatments. Recent studies have shown
that the normal TP53 gene produces many different versions of its protein, and that some of these
naturally occurring forms are found more often in tumors that others. However, it was not clear if
certain versions of TP53’s proteins contributed to the development of cancer.
Now, Gadea, Arsic, Fernandes et al. show that D133p53b, one version of the protein produced
by the TP53 gene in human cells, helps tumor cells to spread to other organs. Tests of 273 tumors
taken from patients with breast cancer revealed that tumors with the D133p53b protein were more
likely to spread. Patients with these D133p53b-containing tumors were also more likely to develop
secondary tumors at other sites in the body and to die within five years.
Next, a series of experiments showed that removing D133p53b from breast cancer cells grown in
the laboratory made them less likely to invade, while adding it back had the opposite effect. The
same thing happened in colon cancer cells grown in the laboratory. The experiments showed that
D133p53b causes tumor cells with the normal TP53 gene or a mutated TP53 gene to spread to other
organs.
Together the new findings help explain why some aggressive cancers develop even with a normal
version of the tumor-suppressing TP53 gene. They also help explain why not all cancers with a
mutant version of the TP53 gene go on to spread. Future studies will be needed to determine
whether drugs that prevent the production of the D133p53b protein can help to treat aggressive
cancers.
DOI: 10.7554/eLife.14734.002
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promote EMT, inducing cancer cells to leave their primary tumor site and disseminate, leading to
metastasis (Bernard et al., 2013; Gadea et al., 2007; Muller et al., 2009; Roger et al., 2010). How-
ever, there remain many enigmas concerning the association of p53 expression with cancer progres-
sion and treatment largely due to the natural existence of multiple alternative transcripts from the
TP53 gene. (De Roock et al., 2009; Brosh and Rotter, 2009; Petitjean et al., 2007; Soussi, 2007).
The main focus of this study is the role of D133p53b in cancer progression. We show that
D133p53b is associated with poor prognosis in breast cancer, particularly in luminal A breast cancer
patients who express WT TP53. This indicates that D133p53b, which is a physiological gene product
of TP53, is a predictor of cancer cell invasion and increased risk of death. We corroborate the clinical
analysis by demonstrating experimentally that D133p53b promotes invasion using a panel of breast
cancer cell models expressing WT and mutant TP53 gene. Similar results were obtained in a panel of
colon cancer cell lines. Depletion of endogenous mutant D133p53b prevents invasiveness despite
unaltered strong expression of mutant TAp53a. Reciprocally, introduction of WT D133p53b pro-
motes invasion of WT TP53 cells devoid of endogenous D133p53b expression. Altogether, our data
indicate that cell invasiveness is regulated by D133p53b irrespective of whether they harbor a mutant
or a WT p53 gene.
Challenging the paradigm that WT TP53 always acts as a tumor suppressor protein, our data
show that the WT TP53 gene can also promote invasiveness by encoding D133p53b. Hence, our
data established that the cell decision is not exclusively determined by canonical full- length p53 pro-
tein (TAp53a), either mutant or WT, but by the modular protein complex of p53 isoforms, which
reprogram epithelial cells to pro-metastatic cells.
Results
Association between D133p53 isoforms expression and breast cancer
clinico-pathological subtypes
The association of D133p53 (a, b, g) isoforms with prognosis has not previously been investigated in
breast cancer. As there is no antibody specific of D133p53a, D133p53b or D133p53g protein isoform,
we developed a nested RT-PCR method that specifically detects and identifies D133p53a, D133p53b
or D133p53g mRNA variants in tumor samples. Briefly, the RT-PCR method is based on the previ-
ously described RT-PCR method (Khoury et al., 2013) but its sensitivity and specificity have been
improved (A fully detailed protocol is provided in the ’Extended Experimental Procedure’ section
and the primer sequences are described in Table 1). It enables to specifically detect and identify
expression of D133p53a, D133p53b or D133p53g mRNA variants in tumor samples. This nested RT-
PCR analysis allows thus to investigate the association of D133p53a, D133p53b or D133p53g expres-
sion with the clinico-pathological markers and/or patient clinical outcome.
Total RNAs were extracted from 273 randomly selected primary breast tumors (Figures 1A,B and
Table 1). Expression of D133p53a mRNA was detected in 97/273 (35.5%), D133p53b mRNA in 23/
273 (8.4%) and D133p53g mRNA in 56/221 (25.3%) of the breast tumors analyzed (Table 2). To verify
that detection of D133p53b mRNA is associated with D133p53b protein expression, protein extracts
from 8 large breast tumors were analyzed by SDS-PAGE and western-blot with KJC8, a beta p53
specific antibody (Figure 1—figure supplement 2). Samples identified as expressing D133p53b
mRNA also express D133p53b at the protein level, confirming the RT-PCR analysis data and that
D133p53b protein is expressed in tumor samples.
D133p53b or D133p53g are tightly associated with D133p53a expression [21/23 (91.3%); 53/56
(94.6%), respectively]. Almost all tumors expressing D133p53b express D133p53a. However, only
25% of tumors expressing D133p53g also express D133p53b (14/56, Table 3). The strong association
of D133p53a with either the D133p53b or D133p53g isoforms is consistent with the fact that the
three mRNAs are initiated from the same promoter in intron-4 of the human TP53 gene
(Bourdon et al., 2005).
We analyzed the association of D133p53a, D133p53b, and D133p53g with the current clinico-
pathological subtypes of breast cancer: luminal A (ER+, PR+, HER2-), luminal B (ER+, PR , HER2-),
luminal/HER2+ (ER+, PR+/-, HER2+), HER2 positive (ER-, PR-, HER2+), and triple negative (ER-, PR-,
HER2-), according to the recommendations of St Gallen International expert consensus
(Goldhirsch et al., 2013). None of the three isoforms were associated with histological cancer type,
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number of metastatic lymph nodes, tumor size or grade (Table 4) and neither D133p53a nor
D133p53g were associated with breast cancer subtypes. However, D133p53b was significantly less
frequently expressed in HER2 positive and luminal/HER2+ tumors than in other breast cancer sub-
types (2/69, Fisher’s exact test, p0.042, Figure 1C). TP53 mutations were identified in 64 tumors
(64/260, 24.6%). D133p53b expression was significantly associated with TP53 mutation status (c2
= 5.625, p0.018, Figure 1C), whereas D133p53a and D133p53g expression levels were not
(Table 2). In all tumors, D133p53a, D133p53b or D133p53g carried the same TP53 gene mutation,
indicating that all the corresponding mRNAs derive from cancer cells and not from normal stromal
or inflammatory cells.
Altogether, these data indicate that almost all tumors expressing D133p53b and/or D133p53g
also express D133p53a. However, D133p53b is distinct from D133p53a and D133p53g, in that it is
less frequently detected in breast tumors overexpressing HER2 and more frequently expressed in
tumors expressing mutant p53 than in tumors expressing WT p53. Therefore, D133p53a, D133p53b,
and D133p53g are not randomly expressed.
D133p53b expression and prognosis in primary breast cancer
The association of D133p53a, D133p53b, and D133p53g expression with cancer patient outcome
(cancer progression/disease-free survival and overall survival/death) was investigated by univariate
analysis of our cohort of breast tumors. D133p53b was associated with cancer progression (CP) and
death (CP: c2 = 5.953, p0.015, death: c2 = 7.126, p0.008) (Figure 1C), while D133p53a and
D133p53g were not. This was further confirmed by Kaplan-Meier log-rank analyses (Kaplan-Meier
log-rank test, CP: c2 = 6.221, 1 df, p0.013; death: c2 = 5.731, 1 df, p 0.017, Figures 1D,E,F, Fig-
ure 1—figures supplement 1A,B and C). Importantly, D133p53b expression was also associated
with cancer progression in WT TP53 breast cancer patients (Kaplan-Meier log-rank test, CP: c2 =
5.232, p0.022) (Figure 1—figure supplement 1I), indicating that the association between
D133p53b expression and cancer progression is not due to TP53 mutation. (Of note the Kaplan-
Meier log-rank analyses were also performed for D133p53a or D133p53g in WT TP53 breast cancer
Table 1. Primers for specific amplification of D133p53 isoforms mRNAs by nested RT-PCR. The specific region (exon or intron) that
each of the primers target is indicated (Ex: exon; Int: intron), the sequences corresponding to the exon junction are underlined. (F):
Forward, (R): Reverse. PCR fragment sizes (bp) corresponding to p53 isoforms are also highlighted. Quality of reverse-transcription is
assessed by quantitative RT-PCR amplification (SybrGreen) of actin and p53 mRNAs (primers are included)
p53 mRNA
variant PCR Primer name and targeted region 5’ – 3’ sequence
All p53 mRNA For6 (F) (Ex6) TTGCGTGTGGAGTATTTGGAT
Rev7 (R) (Ex7) TGTAGTGGATGGTGGTACAGTCAGA
D133p53a 1st D133F1 (F) (Int4) TAGACGCCAACTCTCTCTAG
Rev10 (R) (Ex10) CTT CCC AGC CTG GGC ATC CTT G
2nd
(670bp)
D133F2 (F) (Int4) ACT CTG TCT CCT TCC TCT TCC TAC AG
RDNp53 (R) (Ex9/Ex10) CTC ACG CCC ACG GAT CTG A
D133p53b 1st D133F1 (F) (Int4) TAGACGCCAACTCTCTCTAG
Rev10 (R) (Ex10) CTT CCC AGC CTG GGC ATC CTT G
2nd
(700bp)
D133F2 (F) (Int4) ACT CTG TCT CCT TCC TCT TCC TAC AG
p53b (R) (Ex9b) TCA TAG AAC CAT TTT CAT GCT CTC TT
D133p53g 1st D133F1 (F) (Int4) TAGACGCCAACTCTCTCTAG
Rev10 (R) (Ex10) CTT CCC AGC CTG GGC ATC CTT G
2nd
(670bp)
D133F2 (F) (Int4) ACT CTG TCT CCT TCC TCT TCC TAC AG
p53g (R) (Ex9/Ex9g ) TCGTAAGTCAAGTAGCATCTGAAGG
actin actin (F) ATCTGGCACCACACCTTCTACAATGAGCTGCG
actin (R) CGTCATACTCCTGCTTGCTGATCCACATCTGC
DOI: 10.7554/eLife.14734.003
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Figure 1. Breast cancer patients expressing D133p53b have a poor clinical outcome. (A) Schematic representation of human TAp53a, D133p53a,
D133p53b and D133p53g protein isoforms. The two transactivation domains [TADI (in light purple) and TADII (in pink)] the Proline-rich Domain (PrD), the
DNA-Binding Domain (DBD in orange), and the C-terminal domain comprised of the nuclear localization signal (NLS; in yellow), the oligomerization
domain (OD; in blue), and the basic region (BR; in violet) are represented. The grey boxes correspond to the five highly conserved regions defining the
p53 protein family. The amino-acid positions defining the different p53 domains are indicated. The C-terminal domains of p53b (DQTSFQKENC) and
p53g (MLLDLRWCYFLINSS) are indicated by green and pink respectively. The molecular weight (kD) of each p53 isoform protein is indicated. (B)
Specific nested RT-PCR amplification of D133p53a, D133p53b and D133p53g. Total RNAs from 273 primary breast tumors were provided by the Tayside
tissue bank. The quality of RNA and the quality of reverse-transcription were assessed as described in Materials and methods section. All samples with
low RNA quality and low quality of reverse transcription were discarded to minimize the number of false negative. Each different p53 cDNAs were
specifically amplified by 2 successive nested RT-PCR (35 cycles each) using 2 sets of the primer specific of each of the following p53 mRNA variants: p53
(all isoforms), D133p53a, D133p53b and D133p53g . The nested RT-PCR analysis was performed as described in the Materials and methods section and
the extended experimental procedures. Primer sequences are provided in Table 1 . A representative subset of the nested RT-PCR analysis is shown.
Tumor sample numbers are indicated. C: negative control, M: Molecular Markers. (C) D133p53b association with TP53 gene mutation status, HER2 and
clinical outcome in breast cancer patients. D133p53b expression is associated with p53 mutation but is not frequently expressed in HER2 positive
tumors as determined by univariate analysis (upper table). D133p53b expression is associated with cancer progression and death in breast cancer by
univariate analysis. (Lower table) (D–F) Only D133p53b is associated with cancer progression in breast cancer patients. Non-parametric Kaplan-Meier
plots of disease-free survival in relation to D133p53a (D), D133p53b (E), D133p53g (F) expression (n = 273). ‘I’ indicates censored cases on the curves.
p-value is based on Kaplan-Meier log-rank analyses.
DOI: 10.7554/eLife.14734.004
The following figure supplements are available for figure 1:
Figure 1 continued on next page
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patients. Their respective expression was not found associated with clinical outcome of WT TP53
breast cancer patients.)
In addition to D133p53b expression, other well-established markers of cancer prognosis such as
the breast cancer subtypes, TP53 mutation, tumor grade, lymph node metastasis (absence or pres-
ence) and tumor size (>20 mm) were, as expected, also associated with cancer patient outcome in
our cohort (Figure 1—figures supplement 1D–H). To clarify the univariate analyses and adjust for
possible confounding variables, the association of overall survival and disease-free survival with
D133p53b, the breast cancer subtypes (luminal-A, luminal-B, HER2+, triple-negative and luminal/
HER2+), TP53 mutation, tumor grade, lymph node metastasis and/or tumor size (>20 mm) were
investigated using the multivariate Cox’s regression analysis. The cohort was composed of 112 lumi-
nal-A, 43 luminal-B, 49 luminal/HER2+, 20 HER2+ and 49 triple-negative tumors. We observed that
Figure 1 continued
Figure supplement 1. Non-parametric Kaplan-Meier plots analysis of marker association with disease-free survival and overall survival in the entire
cohort of primary breast cancers (related to Figure 1).
DOI: 10.7554/eLife.14734.005
Figure supplement 2. Detection of endogenous beta p53 protein isoforms in breast tumors(related to Figure 1).
DOI: 10.7554/eLife.14734.006
Table 2. characteristics of breast tumors in the Tayside cohort.
Variables
Primary breast tumors 273
median age
follow up
61.5 (range 28.7–89.1 years)
6.85 (0.29–13.7 years)
grade 1
2
3
unknown
25
85
159
4
type ductal
others
220
53
clinico-pathological subtype triple-negatif
luminal A
luminal B
HER2+
luminal/HER2+
49
112
43
20
49
size <20 mm
>20 mm
unknown
91
180
2
invaded lymph nodes
(node>0)
negatif
positif
unknown
132
140
1
patient outcome disease free
recurrence
alive
death
201
72
196
77
p53 Wild-type
mutant
unknown*
196
64
13
D133p53a -
+
176
97
D133p53b -
+
250
23
D133p53g -
+
unknown*
165
56
52
DOI: 10.7554/eLife.14734.007
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the luminal-A subtype was, as expected, the most significant independent predictor of disease-free
survival (HR = 3.09, 95% CI, 1.78 to 5.38, p<1.10–4) and overall survival (HR = 4.15, 95% CI, 2 to
8.62, p<1.6 10–4, Table 5A). Then, we examined by multivariate Cox’s regression analysis the level
of inter-dependence between D133p53b, TP53 mutation, tumor grade, lymph node metastasis
(absence or presence) and tumor size (>20 mm) in the luminal-A breast cancer population (n = 112).
We determined by an Omnibus test of model coefficient that the Cox-regression model is fitted (c2
= 17.589, 1 df, p<2.7 10–5), indicating that the number of luminal-A tumors in our cohort is sufficient
to support the conclusions. Among all the parameters included in the analysis (D133p53b, TP53
mutation, tumor grade, lymph node metastasis and tumor size [>20 mm]), D133p53b stood out as
the most significant independent predictor of cancer recurrence and death within the luminal-A sub-
group regardless of TP53 mutation status or presence of lymph node metastasis (Hazard ratio [HR],
7.93; 95% CI, 2.52 to 25; p<4.31 10–4; [HR], 3.29; 95% CI, 1.125 to 9.63; p<0.03, Table 5B, respec-
tively). It implies that at the time of surgery, detection of D133p53b in primary luminal-A breast
tumors of patients devoid of lymph node would predict cancer progression. Of note, the multivariate
Table 3. Repartition of D133p53 isoforms in the Tayside breast cancer cohort (2x2 table). (A)
D133p53a X D133p53b. (B) D133p53a X D133p53g . (C) D133p53b X D133p53g ( ) not detected, (+)
amplified.
A
D133p53a
  + Total
D133p53b  
+
174
2
76
21
250
23
Total 176 97 273
B
D133p53a
  + Total
D133p53g  
+
138
3
27
53
165
56
Total 141 80 221
C
D133p53g
  + Total
D133p53b  
+
156
9
42
14
198
23
Total 165 56 221
DOI: 10.7554/eLife.14734.008
Table 4. Univariate analysis of D133p53 isoforms expression in relation to clinical pathological markers. Tumor grade, cancer type
(ductal or others), tumor size (>or < 20 mm) were analyzed by Fisher’s t-test. Association with the number of invaded lymph nodes
were analyzed by Mann-Whitney method.
grade type size
nb invaded
Lymph nodes1-2 3 p value ductal others p value <20 mm >20 mm p value
D133p53a  
+
76
34
98
61
p<0.21 140
80
36
17
p<0.56 62
29
113
67
p<0.39 p<0.97
D133p53b  
+
102
8
144
15
p<0.54 201
19
49
4
p<0.8 81
10
167
13
p<0.30 p<0.60
D133p53g  
+
75
21
87
35
p<0.25 133
46
32
10
p<0.8 59
19
105
37
p<0.79 p<0.78
DOI: 10.7554/eLife.14734.009
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Cox-regression analysis was also performed for D133p53a and D133p53g but no significant associa-
tion with the clinical outcome of luminal-A breast cancer patients was found.
Thus, D133p53b in luminal-A breast cancer, which predominantly expresses WT TP53, enhances
on average by 8 times the risk of recurrence and by 3 times the risk of death in an otherwise excel-
lent prognostic group. This indicates that WT TP53 gene can be associated with cancer recurrence
and death if it expresses D133p53b.
p53 isoforms are more expressed in highly invasive breast cancer cells
The clinical study suggests that D133p53b may confer a more invasive phenotype to breast cancer
cells. We then compared the ability of three different cancer cell lines to invade into type1- Colla-
gen. We used: (1) luminal MCF7 cells (WT TP53 and ER+), which depend on estrogen and EGF (Epi-
dermal Growth Factor) for their growth and are neither locally invasive nor metastatic in mouse
models, (2) the triple-negative MDA-MB-231 (mutant TP53-R280K, ER-), which was derived from a
pleural effusion metastasis, and (3) its ‘D3H2LN’ variant (mutant TP53-R280K, ER-), which was
selected for their enhanced tumor growth and widespread metastasis in mice (Jenkins et al., 2005).
As expected, MCF7 cells were very weakly invasive and MDA-MB-231 D3H2LN cells showed a
significantly higher invasiveness as compared to parental MDA-MB-231 cells (Figure 2A). The differ-
ence between MCF7 cells and the two MDA-MB-231 cell lines may result from their TP53 status,
since mutant TAp53a protein can activate cell migration, invasion and metastasis (Gadea et al.,
2007, 2002; Muller et al., 2009; Roger et al., 2010). However, the difference in invasion between
the two MDA-MB-231 cell types expressing the same mutant TP53 gene suggests the presence of
another mechanism activated in the D3H2LN variant cell line. We examined whether this could be
due to differential expression of the p53 isoforms. By quantitative real-time-PCR (RT-qPCR) using
primers and probe (TaqMan) specific of the different subclasses of TP53 mRNA variants TAp53,
D133 and alpha, beta and gamma (intron-9 splice variants) (Khoury et al., 2013), we found that
whereas the two cell lines expressed similar levels of TAp53 and alpha TP53 mRNA variants, the
more invasive MDA-MB-231 D3H2LN expressed higher levels of D133p53, beta and gamma mRNA
variants (Figure 2B). We confirmed, by western blotting, the highest expression level of p53 protein
isoforms in MDA-MB-231 D3H2LN cells by using a sheep polyclonal anti-p53 antibody (Sapu), which
recognizes each p53 protein isoform with high specificity (Marcel et al., 2013). By western blotting,
eight bands at 28, 35, 38, 40, 42, 45, 47, and 51 kDa were revealed in mock-transfected cells.
(Figure 2C, mock lanes a and b). All these bands correspond to genuine p53 protein isoforms as
Table 5. Multivariate analysis of predictor. (A) Multivariate Cox’s Regression analyses utilizing the forward step-wise elimination
method to determine the degree of inter-dependence between the breast cancer subtypes (triple negative, Luminal A, Luminal/HER2
+, Luminal B, and HER2+), D133p53b, TP53 mutation status, lymph node metastasis (present versus absent), tumor size and tumor
grade in relation to disease-free survival and overall survival. (B) Multivariate Cox’s Regression analyses utilizing the forward step-wise
elimination method to determine the degree of inter-dependence between D133p53bTP53 mutation status, lymph node metastasis
(present versus absent), tumor size and tumor grade in the luminal A breast cancer patient population. The Fitted model was assessed
by an Omnibus test. Hazard Ratio (HR), 95% confidence interval (CI), p values, number of iteration (itr) are indicated.
A
n = 273 omnibus test of model coefficients
itr. predictor c2 df p-value HR 95% CI p-value
Disease-free
survival
1 Luminal A 17.389 1 3.00E-05 3.09 1.78 5.38 1.00E-04
Overall
survival
1 Luminal A 17.088 1 3.50E-05 4.15 2 8.62 1.60E-4
B
n = 112 omnibus test of model coefficients
itr. predictor c2 df p-value HR 95% CI p-value
Recurrence 1 D133p53b 17.589 1 2.70E-05 7.93 2.52 24,96 4.31E-04
Death 1 D133p53b 5.31 1 2.10E-02 3.29 1.12 9.63 3.00E-02
DOI: 10.7554/eLife.14734.010
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they disappear after transfection with siRNA siE7 which targets exon-7 that is present in all p53
mRNA variants (lanes ’siE7’) (Aoubala et al., 2011; Camus et al., 2012; Terrier et al., 2012). In
agreement with the RT-qPCR data, TAp53a protein expression is similar between MDA-MB-231 and
MDA-MB-231 D3H2LN, while all the other p53 protein isoforms, notably D133p53b are expressed at
higher levels in MDA-MB-231 D3H2LN. This suggests that the enhanced invasiveness of MDA-MB-
231 D3H2LN is not due to variation of mutant TAp53a protein expression level (Figure 2C, all lanes
compare b to a).
D133p53 isoforms control breast cancer cell invasion
To address the role of mutant D133p53 isoforms in the enhanced invasiveness of MDA-MB-231
D3H2LN cells, we analyzed cells depleted either of all D133p53 isoforms (by using the siRNAs si133-
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Figure 2. p53 isoform expression correlates with cell invasiveness in breast cancer cells. (A) Invasion of breast cancer cell lines. MCF7, MDA-MB231 and
MDA-MB231 D3H2LN cells were assayed for 24 hr and the changes in invasion were analyzed, as described in Materials and methods (Smith et al.,
2008). Invading cells were counted as the number of invading cells at 50 mm divided by the number of non-invading cells at 0 mm. The results are
expressed as the fold change ratio compared with MDA-MB231. Each assay was performed in triplicate for each cell line. The values plotted are means
± SEMs of N = 4 independent experiments; *p<0.05. (B) Comparative expression of p53 mRNA variants in MDA-MB231 D3H2LN versus parental MDA-
MB231 cells. The expression level of p53 isoform mRNA is higher in the highly invasive MDA-MB231 D3H2LN cells than in MDA-MB231 cells. Sub-
confluent proliferating breast cancer cells were harvested for quantitative RT-qPCR Taqman assays (see Materials and methods section). p53 isoform
expression was quantified relative to the control MDA-MB231 cell line. For all RT-qPCR experiments, expression levels of p53 isoforms were normalized
to TBP. Results are expressed as the fold change compared to MDA-MB231 cells and represent means ± SEMs of N = 4 independent experiments;
*p<0.05. (C) Differential expression of endogenous p53 protein isoforms in MDA-MB231 and MDA-MB231 D3H2LN cells. The protein expression levels
of p53 isoforms were analyzed by western blotting using the sheep polyclonal p53 pantropic antibody (Sapu). To identify p53 protein isoforms, cells
were transfected either with p53 siRNA (siE7) targeting exon-7 common to all p53 mRNA variants or with control siRNA (siNS, non specific). Two
exposures (short and long) are shown.
DOI: 10.7554/eLife.14734.011
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1 or si133-2, which specifically target the 5’UTR of all D133 mRNAs [Aoubala et al., 2011]), or of all
b isoforms (by using sib, [Camus et al., 2012; Terrier et al., 2012]), or of all p53 isoforms except
D133p53 (a, b, g) by using siTAp53, a siRNA targeting p53 mRNA splice variant containing TP53
exon-2 (Figure 3A). We assessed knockdown efficacy by RT-qPCR and western blotting using the
Sapu and KJC8 antibodies (Figures 3D and Figure 3—figure supplement 1A). Importantly, deple-
tion of D133 or b p53 variants (by transfection of si133-1, si133-2 or sib) significantly decreased the
invasiveness of mutant TP53 MDA-MB-231 D3H2LN cells without altering the expression of mutant
TAp53a protein (Figure 3D). However, depletion of all p53 isoforms except D133p53 (a, b, g ) by
siTA did not change the invasive activity of MDA-MB-231 D3H2LN cells, indicating that the simulta-
neous depletion of all TAp53 (including mutant TAp53a) did not impair MDA-MB-231 D3H2LN cell
invasion (Figures 3B and Figure 3—figures supplement 1A). To confirm the role of the D133p53b
isoform in promoting invasion potential, we re-introduced a si-resistant D133p53b-R280K isoform in
MDA-MB-231 D3H2LN cells in which all D133p53 (a, b, g) isoforms had been knocked down with
si133-1 or si133-2. As expected, expression of the si133-1- and si133-2- resistant D133p53b-R280K
rescued invasion (Figure 3C and Figure 3—figure supplement 1B). Similarly, D133p53b-R280K
expression rescued invasion when cells were depleted of all b isoforms by sib (Figure 3C and Fig-
ure 3—figure supplement 1C). We then compared the effects of D133p53a-R280K, D133p53b-
R280K and D133p53g-R280K isoforms on cell invasion. As the siRNAs si133-1 and si133-2 specifically
target the 5’UTR of all D133 mRNAs, we tested their respective contribution to the invasive pheno-
type by re-introducing each of them in MDA-MB-231 D3H2LN cells in which all D133p53 (a, b, g ) iso-
forms had been knocked down with si133-1 or si133-2. All three mutant D133p53 isoforms rescued
invasion in cells depleted of D133p53 variants, with D133p53b-R280K conferring the highest invasive
activity compared to D133p53a-R280K or D133p53g-R280K (Figure 3C and Figure 3—figure sup-
plement 1B). These results indicate that mutant D133p53 isoforms, notably the D133p53b variant,
are sufficient to promote invasion in mutant TP53 MDA-MB-231 D3H2LN cells, consistently with an
active role for D133p53b isoform in cancer progression.
EMT is a gatekeeper process involving global cell reprogramming leading to profound pheno-
typic changes that include enhanced invasiveness along with loss of epithelial cell-cell adhesion pro-
teins such as E-Cadherin and concomitant gain of mesenchymal protein expression including
Vimentin and N-Cadherin. EMT is a reversible process, thus mesenchymal cells can reverse their phe-
notype and re-express epithelial markers (Thiery et al., 2009). Interestingly, depletion of mutant
D133 or b p53 isoforms reversed mesenchymal traits of MDA-MB-231 D3H2LN cells, by inducing a
significant induction of E-Cadherin protein expression and a marked decrease in Vimentin expres-
sion, particularly in cells transfected with sib. Knockdown efficacy was assessed by western blotting
using the p53 pantropic polyclonal sapu and b-specific KJC8 antibodies (Figure 3D). Thus, inhibition
of endogenous mutant D133 or b p53 isoforms induced a switch in the expression of these epithelial
features which reflects global reversion of EMT cell reprogramming. Interestingly, re-epithelialization
was impaired upon depletion of all p53 isoforms (Figure 3D, lane siE7), suggesting that other p53
splice variants control epithelial features. Differential induction of E-Cadherin expression was also
observed at the mRNA level (Figure 3E).
We then addressed whether the introduction of WT D133p53b in MCF7 cells that endogenously
express all p53 isoforms except D133p53b and D133p53g (Figure 3—figure supplement 1D) pro-
motes invasion. As shown in Figure 3F and Figure 3—figure supplement 1E, WT D133p53b trig-
gered MCF7 cell invasion into type1-Collagen.
Altogether, the results in MDA-MB-231 D3H2LN and in MCF7 indicate that mutant and WT
D133p53b promote invasion of WT and mutant TP53 breast cancer cells. In mutant TP53 cells
expressing D133p53b, depletion of TAp53a does not inhibit cell invasion, while depletion of the
D133p53 or b p53 isoforms decreases invasion of cells expressing mutant TAp53a. In WT TP53 cells
expressing all p53 isoforms except D133p53b, introduction of WT D133p53b promotes invasion. It
suggests an active role for WT and mutant D133p53b in cancer progression corroborating the clinical
analysis.
D133p53 isoforms are required for colon cancer cell invasion
To determine whether D133p53b can promote invasion in other cancer types regardless of TP53
mutation status, we studied a panel of WT and mutant TP53 cell lines derived from colon carcinoma,
another relevant model for cancer cell invasion, by comparing their ability to invade into Matrigel.
Gadea et al. eLife 2016;5:e14734. DOI: 10.7554/eLife.14734 10 of 26
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Figure 3. D133p53b isoform promotes invasion in breast cancer cells. (A) RNA chart of the different isoforms of TP53 in this study showing the exons
(boxes) and introns (horizontal lines, not to scale). Alternative promoters are shown as arrows and alternative splices are depicted with the lines above
as they connect different exons. Location of the different siRNAs used is indicated below the chart. Below is a list of the p53 isoforms that remain after
transfection of the different siRNAs, indicated by a cross. (B) Specific inhibition of some p53 isoforms expression decreases invasiveness. MDA-MB231
Figure 3 continued on next page
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The cell lines used were derived from the primary colorectal carcinoma (CRC): HCT116 (WT TP53)
and SW480 (mutant p53R273H), and from metastatic tumors: LoVo (WT TP53), SW620 (mutant
p53R273H) and CoLo205 (mutant p53, Y103 del27bp). Of note, the SW620 cell line was derived
from a metastasis of the primary tumor from which the SW480 cell line was derived one year earlier.
Compared to cells derived from primary colon tumors, metastasis-derived cell lines expressing WT
or mutant TP53 exhibited a higher ability to invade Matrigel (Figure 4A) and had no E-Cadherin at
cell-cell junctions (Figure 4B). Of note, although the SW620 and SW480 cell lines have a mutated
TP53 gene (R273H) and come from the same patient, only SW620 are highly invasive, indicating that
the expression of mutant TAp53a-R273H protein is not sufficient to explain invasive activities. We
thus measured D133p53 mRNA expression by RT-qPCR (Taqman) and found it significantly higher in
the invasive cell lines whether they express WT or mutant TP53 gene, i.e. LoVo, SW620 and
CoLo205, as compared with HCT116 and SW480 cell lines (Figure 4C), in agreement with the results
obtained in the breast cancer cell lines. To confirm the role of D133p53 isoforms in cell invasion, we
knocked-down these isoforms in mutant TP53 SW620, or WT TP53 LoVo CRC cells by using si133-1
and si133-2, which led to a significant decrease invasive capacity in both cell lines (Figure 4D and
Figure 4—figures supplement 1A and B). As expected, re-introduction of si133-1-resistant WT
D133p53b rescued invasiveness of LoVo cells depleted of D133p53 isoforms by si133-1 (Figure 4—
figures supplement 1C and D). This indicates that D133p53 isoforms, notably D133p53b, regulate
invasion, irrespectively of TP53 mutation status.
Among WT TP53 colon carcinoma cells, HCT116 are weakly invasive and endogenously express
all p53 protein isoforms, including D133p53b (Figure 4E). We investigated whether we could modify
HCT116 cell invasion by modulating the ratios of p53 isoforms. First, we depleted endogenous
expression of different p53 isoforms using specific siRNAs and compared the invasiveness of
HCT116 cells depleted of all p53 proteins other than D133p53 isoforms (i.e. transfected with the
siTAp53 siRNA) or depleted of b isoforms but still expressing TAp53a (i.e. transfected with the sib
siRNA) (Aoubala et al., 2011; Marcel et al., 2014) (Figure 4F).
HCT116 cells transfected with siTAp53 are more invasive than cells transfected with siNS or siE7,
while HCT116 cells transfected with sib, which depleted p53b, D40p53b and D133p53b are less inva-
sive than cells transfected with siNS (Figure 4E and F). This suggests that the ratio of TAp53 and b
isoforms, including D133p53b, defines the invasive activity of HCT116 cells. Altogether our data indi-
cate that the invasive capacity of colon cancer cell lines, as in the breast tumor cell lines, correlates
with and depends on the expression of D133p53 isoforms, regardless of the TP53 mutation status.
Figure 3 continued
D3H2LN cells were transfected with si133-1 or si133-2, two distinct siRNAs specific for the 5’UTR of D133p53 mRNAs; or with siTAp53, a siRNA targeting
TP53 exon-2 depleting all p53 isoforms except the D133p53 (a, b, g) isoforms; or with sib, a siRNA targeting the alternatively spliced exon-9b of TP53; or
with siNS, a non-specific siRNA used as negative control. (C) ’ Rescue’ experiments. Re-introductions of si-133–resistant mutant D133p53a-R280K,
D133p53b-R280K or D133p53g-R280K restore the invasive activity in MDA-MB231 D3H2LN cells previously depleted of either D133p53 (a, b, g ) isoforms
after transfection with si133-1 or si133-2, or b p53 isoforms (p53b, D40p53b and D133p53b) (n = 4). (D) Inhibition of endogenous p53 protein isoforms
induces expression of epithelial features associated with decreased invasiveness. The expression of endogenous p53 protein isoforms after transfection
of MDA-MB231 D3H2LN cells with si133-2, sib, siE7 or control siRNA (siNS) was analyzed by western blotting using pantropic p53 isoforms antibody
Sapu or KJC8, a b-specific p53 antibody recognizing p53b, D40p53b and D133p53b. The expression of two EMT markers (Vimentin and E-Cadherin) was
determined in parallel. Ku80 was used as a loading control. * cross-reaction. (E) Quantification of E-Cadherin mRNA in MDA-MB231 D3H2LN cells
transfected with siRNA si133-2, sib, siE7 or siNS (control) used as a negative control. For all RT-qPCR experiments, expression levels were normalized to
TBP. Results are expressed relative to TBP mRNA and represent means ± SEMs of N = 4 independent experiments; *p<0.05; **p<0.01 (F) WT D133p53b
promotes cell invasion. Weakly invasive MCF7 cells were transfected with D133p53b expression vector or the empty expression vector (Control). Cells
were challenged for their invasive potential after 48 hr. The values are plotted as means ± SEMs of at least 3 independent experiments; *p<0.05.
DOI: 10.7554/eLife.14734.012
The following figure supplement is available for figure 3:
Figure supplement 1. D133p53 (a, b and g ) expression in MCF7 breast cancer cells (related to Figure 3).
DOI: 10.7554/eLife.14734.013
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Figure 4. D133p53 isoforms promote invasion in colorectal cancer cells. (A) Invasiveness of different colorectal cancer cells. Cells were assayed for
invasiveness through Matrigel over 24 hr, as described in Materials and methods. Invading cells were counted and the results are expressed as the
average of 6 different fields and normalized to HCT116 cells. Each assay was performed in triplicate for each cell line. TP53 mutation status is indicated.
The values plotted are means ± SEMs of N = 4 independent experiments. (B) Immunofluorescence staining for E-Cadherin in a panel of colorectal cell
Figure 4 continued on next page
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D133p53b induces invasiveness and an amoeboid-like phenotype in WT
TP53 colon carcinoma cells
To determine whether the D133p53b-enhanced invasion directly impacts on the mode of cell migra-
tion, we transfected HCT116 with GFP- WT D133p53b and tracked them by video-microscopy. We
observed two populations of cells, cohesive epithelial cells adherent to the glass and rounded cells
loosely attached on top of cohesive cells. GFP-tagged D133p53b expression elicited a significant
increase of rounded cells with dynamic bleb-like structures on their surface (Figure 5A, Video 1 and
Figure 5—figure supplement 1A as control). While recording, we noticed that some GFP-D
133p53b -positive cohesive adherent cells detached progressively from the substratum, became
rounded (white arrowhead, Figure 5A) and migrated (white arrow, Figure 5A). Propidium iodide
staining and FACS analysis showed that blebbing cells were alive and were not undergoing apopto-
sis (Figure 5—figure supplement 1B). The number of blebbing cells was 25 times greater than the
number of adherent cells in HCT116 cells transfected with D133p53b (Figure 5B). Similar rounded
and detached cells were obtained using myc-tagged isoforms, ruling out any role of GFP in the
observed phenotype (Figure 5B). Since loss of adhesive structures and concomitant acquisition of a
rounded-blebbing movement are hallmarks of epithelial-amoeboid transition (EAT), a derivative of
EMT which produce highly invasive cells, we further confirmed the EAT-like phenotype of D133p53b-
expressing cells by measuring E-cadherin and b1-integrin levels, as the loss of both is a marker of
EAT (Friedl and Wolf, 2003). As shown in Figure 5C,E-cadherin and b1-integrin, expressed at high
levels in adherent cohesive cells, were barely detected in blebbing cells, implying they had experi-
enced EAT. D133p53b also enhanced cell migration and invasion, since its expression in HCT116
cells elicited a two-fold increase in migration (Figure 5D) in uncoated transwell chambers and con-
ferred a 5 times higher invasive capacity in Matrigel (Figure 5D) compared to GFP-only-transfected
controls.
Our data indicate that expression of WT D133p53b promotes EAT in WT TP53 HCT116 cells
which endogenously express low levels of D133p53b. We therefore next investigated whether we
could modify EMT/EAT features in WT TP53 CRC cells that endogenously express high levels of
D133p53b. The WT TP53 colon carcinoma LoVo cells are strongly invasive and endogenously highly
express D133p53 isoforms at the mRNA and protein levels (Figure 4A,C). Knockdown of D133p53
isoforms in LoVo cells remarkably decreased 3-D cell scattering, a process which shares cellular fea-
tures reminiscent of cells undergoing EMT/EAT (Figure 5E and Figure 5—figure supplement 1C).
To investigate the impact of p53 isoforms-mediated cell scattering on the process of migration, we
performed wound-healing assay. LoVo transduced with control shNS progressively detached and
migrated as individual cells (arrows, Figure 5F). LoVo depleted of D133p53 isoforms still remain
cohesive and migrate very slowly into the gap. In this case, some rare clusters of cells leave the cohe-
sive epithelium to enter into the gap (arrowheads, Figure 5F). Interestingly, the cluster of cells
remains compact and cells move collectively, but with a reduced velocity compared to individual
migrating cells with unaffected D133p53 expression (Figure 5F and Videos 2 and 3). Thus
Figure 4 continued
lines. The images show representative E-Cadherin immunostaining for each colorectal cell line plated at low density. Scale bar: 10 mm. (C) Quantitative
RT-qPCR (TaqMan) of different subclasses of p53 isoform mRNA in a panel of colorectal cell lines. Sub-confluent proliferating colorectal cells were
harvested for quantitative RT-PCR assays (see Materials and methods section). For each cell line, results are expressed as the fold change compared to
HCT116 cells. For all RT-qPCR experiments, expression levels of sub-types of p53 mRNA variants were normalized to TBP mRNA and represent means
± SEMs of N = 3 independent experiments; *p<0.05. (D) Invasion of SW620 (left) or LoVo (right) colon cancer cell lines after depletion of D133p53 (a, b,
g) isoforms. Cells transfected with D133 siRNAs (si133-1 and si133-2) or siNS were examined for their invasive potential after 24 hr. Invading cells were
counted and the results are expressed as the average of 6 different fields and normalized to siNS. The values are plotted as means ± SEMs of 3
independent experiments; *p<0.05. (E) Western-blot analysis of endogenous p53 protein isoforms in HCT116 cells transfected with the non-specific
siRNA (siNS) or with p53 isoform specific siRNA siE7, siTAp53, or sib. Cells were then assessed for their invasive potential as in Figure 4F. (F) HCT116
cells transfected with siE7, siTAp53, sib, or siNS were assessed for their invasive potential. Invading cells were counted and the results are expressed as
the average of 6 different fields.
DOI: 10.7554/eLife.14734.014
The following figure supplement is available for figure 4:
Figure supplement 1. D133p53 (a, b and g ) expression and effect on cell invasion using colorectal cancer cells.
DOI: 10.7554/eLife.14734.015
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Figure 5. HCT116 cells expressing the D133p53b isoform display amoeboid-like movements. (A) Still time-lapse images of the accompanying video
(Supplementary data, video1) of HCT116 cells transfected with the GFP-tagged D133p53b isoform. Cells were observed 48 hr after transfection. For the
video, images were captured every 4 min during 12 hr. The panel represents 1/10 images i.e. one image every 40 min. D133p53b-transfected cells can
be distinguished from non-transfected cells through expression of GFP (green). The D133p53b-transfected cells are rounded and exhibit blebbing
Figure 5 continued on next page
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endogenous D133p53 protein isoforms regulate both the mode of cell motility and the ability to
implement adherens junctions, with a subsequent impact on cell velocity.
Altogether, our data indicate that D133p53b expression elicits hallmarks of EAT/EMT in CRC
cells.
Discussion
All the genetic evidence in the clinic and animal
models indicate, unequivocally, the pivotal and
fundamental role of the TP53 gene in cancer
formation, progression and response to treat-
ment. TP53 is ubiquitously expressed and it
regulates different cell responses such as cell
repair, proliferation, senescence, differentia-
tion, cell migration and cell death in response
to any change of tissue/cell homeostasis, thus
maintaining tissue/cell integrity upon stress or
damage. Consistently, TP53 mutation is the
most frequently mutated gene in human can-
cers and its mutation status is associated with
poor clinical outcome. Any cancer treatments
change cell homeostasis and therefore trigger
TP53-mediated cell responses. It is currently
impossible to accurately predict response to
cancer treatment in the clinic because of the
large variety of TP53-mediated cell responses.
In addition, as missense mutations of TP53 do
not totally abrogate its tumor suppressor activ-
ity and can confer additional biological activi-
ties to TP53 gene, it is very difficult to choose
the most efficient cancer treatment based on
TP53 mutation status (Kruiswijk et al., 2015;
Figure 5 continued
movements on their surface. The arrow shows a cell that detaches from the others and from the dish during the time-lapse. The arrowhead shows a cell
that still adheres to the other epithelial cells and to the substratum at the beginning of the experiment and then becomes progressively rounded. (B)
Quantitative analysis of blebbing versus adherent cell number in the Myc positive cells. FACS analysis of the percentage of non-apoptotic blebbing
Myc-positive HCT116 cells compared to total Myc-positive transfected with cells upon transfection of Myc-D133p53b, or Myc-empty expression vector
(vector). Results were normalized to Myc-empty vector transfected cells. (C) Western blot analysis of the expression of E-Cadherin and b1-integrin in
HCT116 cells expressing the GFP-tagged D133p53b isoform; Control: GFP-tag vector. Adherent: cells still adherent to the substratum; Blebbing: cells
detached from the substratum and showing blebbing movements. Loading normalization was performed using an anti-a-tubulin antibody. (D)
D133p53b-transfected HCT116 cells were quantified for their migration ability after 2 hr of migration through the Boyden chamber or for their
invasiveness after 24 hr of the invasion through Matrigel, as indicated. The values are plotted as means ± SEMs of at least 3 independent experiments.
(E) 3-D LoVo cell scattering. The numbers of scattered cells were quantified using Metamorph software (left). Cells were judged as « scattered » when
individual cells or clusters of cells had lost contact with the main colony, as visualized (right). Values (means ± SEMs) were calculated from 4
independent experiments (n = 48) ***p<0.001. (F) Wound healing assay in LoVo cells infected with shRNA non relevant (shNS: shLuciferase) or
shD133p53. Cells were observed 25 hr after infection. Still time-lapse images of the accompanying videos (Supplementary data, Videos 2 and 3) For
the videos, images were captured every 1 hr during 25 hr. The arrows show cells detaching from the others and migrating as individual cells. The
arrowhead shows a cluster of cells which leaves the cohesive epithelium and which collectively migrate and enter into the gap. (G) Schematic
representation of the role for D133p53b in reprogramming cells toward the invasive process. For WT or mutant TP53 cells devoid of D133p53b
expression, introduction of D133p53b promotes EMT and invasion. Reciprocally WT or mutant TP53 cells expressing D133p53b have enhanced invasive
activity. Depletion of D133p53b reverts EMT and inhibits invasion.
DOI: 10.7554/eLife.14734.017
The following figure supplement is available for figure 5:
Figure supplement 1. Control experiments of D133p53b expression and effects in colon cancer cells.
DOI: 10.7554/eLife.14734.018
Video 1. (related to Figure 5A): DIC light microscopy
of HCT116 cells expressing GFP-D133p53b.
DOI: 10.7554/eLife.14734.016
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Lang et al., 2004; Li et al., 2012;Meek, 2015).
This indicates that major features of the TP53
gene and its pathway have still to be uncov-
ered and understood and this represents a crit-
ical bottleneck preventing major breakthroughs
in cancer treatment.
To date, it is thought that the diverse biological activities associated with TP53 gene expression
are carried out by a single protein isoform, p53 (TAp53a). However, like most human genes, TP53
gene does not express one but at least 12 different p53 protein isoforms which have distinct domain
and activities.
The WT canonical p53 protein (TAp53a) prevents cancer invasion by inhibiting EMT
(Gadea et al., 2007; McDonald et al., 2011; Muller et al., 2011; Roger et al., 2010; Suva et al.,
2013) while the mutant canonical p53 protein (mutant TAp53a) was shown to promote cell invasion
(Adorno et al., 2009; Gadea et al., 2002, 2004; Muller et al., 2009; Roger et al., 2010;
Gadea et al., 2007). However, despite this clear distinction between WT and mutant TP53, the situa-
tion in the clinic is not clear cut, as a mutant TP53 expression in primary tumors does not systemati-
cally lead to metastasis formation and WT TP53 is frequently expressed in metastasis (Dong et al.,
2007; Kalo et al., 2007; Oren and Rotter, 2010).
Little is known about the biological roles and clinical relevance of p53 isoforms in cancer. In this
study, we analyzed the expression of D133p53 isoforms (a, b, g) in relation to clinical outcome in pri-
mary breast cancers. We determined that all tumors expressing D133p53b or D133p53g also co-
express D133p53a. This indicates that D133p53 (a, b, g ) isoforms are not randomly expressed in
breast cancers, confirming that the internal promoter of TP53 and the alternative (b, g ) splicing of
p53 mRNA are regulated in tumor cells (Aoubala et al., 2011; Marcel et al., 2014;
2010; Tang et al., 2013).
We also determined that D133p53b expression is significantly associated with cancer recurrence
in breast cancer patients, even in tumor expressing WT TP53. In particular, D133p53b enhances on
average by eight times the risk of recurrence and by three times the risk of death in luminal A breast
cancer patients, an otherwise excellent prognostic group. Importantly, detection of D133p53b at
time of surgery in primary luminal-A breast tumors of patients devoid of lymph node would predict
cancer progression. Therefore, far from having its function inactivated in Luminal A breast cancer,
the WT TP53 gene would promote breast cancer recurrence and increased risk of death when it
expresses D133p53b.
To corroborate the clinical data, we experimentally investigated how D133p53b could confer cell
invasion and motility to WT and mutant TP53 breast cancer cells. First, we observed that the invasive
Video 2. (related to Figure 5—figure supplement
1F, upper panels).
DOI: 10.7554/eLife.14734.019
Video 3. (Related to Figure 5—figure supplement 1F,
lower panels): DIC light microscopy of Wound healing
assay in LoVo cells infected with shRNA non relevant
(shNS: shLuciferase; Video 2) or shD133p53 (Video 3).
Cells were observed 25 hr after infection. Images were
captured every 1 hr during 25 hr.
DOI: 10.7554/eLife.14734.020
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activity of MCF7, MDA-MB-231 and MDA-MB-231 D3H2LN cells is positively correlated to the
D133p53 mRNA expression level. This was also observed in a panel of WT or mutant TP53 colon can-
cer cell lines. In mutant TP53 MDA-MB-231 D3H2LN breast cancer cells, depletion of endogenous
mutant D133p53 isoforms reduces cell invasion, despite unaltered and strong expression of mutant
full-length p53 (TAp53a) protein. Re-introduction of si-133-resistant mutant D133p53a-R280K,
D133p53b-R280K or D133p53g-R280K in MDA-MB-231D3H2LN cells depleted of D133p53 isoforms
restores their invasive phenotype, with mutant D133p53b-R280K being significantly the most potent.
Importantly, depletion of the p53 protein isoforms with siTA that targets only the p53 proteins con-
taining the transactivation domains (i.e TAp53a, TAp53b, TAp53g , D40p53a, D40p53b, D40p53g )
without altering expression of D133p53 isoform did not change the invasive activity of MDA-MB-231
D3H2LN. This indicates that the simultaneous depletion of all TAp53 (including mutant TAp53a) did
not impair MDA-MB-231 D3H2LN cell invasion.
It has previously been reported that overexpression of mutant TAp53a promotes integrin and
epidermal growth factor receptor (EGFR) recycling, thus driving invasion (Muller et al., 2009). How-
ever, expression of the mutant TAp53a is not sufficient to explain why the triple negative breast can-
cer MDA-MB-231 and its highly metastatic MDA-MB-231 D3H2LN derived clone have different
invasive activity while they both express the same mutant TP53-R280K gene. MDA-MB-231 D3H2LN
cells showed a significantly higher invasiveness as compared to parental MDA-MB-231 cells. Interest-
ingly, MDA-MB-231 D3H2LN expressed higher levels of D133p53 mRNA variants and proteins
(Figure 2B and C). Similar results were observed in mutant TP53 colon cancer cell lines. The SW480
and SW620 colon carcinoma cell lines derive respectively from the primary and secondary tumors
resected from the same patient (Hewitt et al., 2000). Although SW480 and SW620 cells express the
same mutant TP53-R273H gene, SW480 cells are far less invasive than the SW620 cells. Interestingly,
SW480 cells express much less D133p53 mRNAs than the SW620 cells. Importantly, depletion of
endogenous D133p53 isoforms from SW620 cells reduces cell invasion, despite unaltered and strong
expression of mutant TAp53a protein. This indicates that the role of endogenous mutant D133p53
isoforms in promoting invasiveness may be extended to other tissue types and that endogenous
D133p53 isoform expression regulates cancer cell invasion in TP53 mutant colon and breast cancer
cells, irrespective of the full-length p53 (TAp53a) expression.
Importantly, the invasive activity of D133p53 isoforms is not associated with TP53 mutation status
since depletion of D133p53 isoforms in WT TP53 colon carcinoma LoVo cells abolishes their scatter-
ing and invasive activities. D133p53 isoform expression thus explains the inconsistent clinical associa-
tion between TP53 mutation and metastasis.
Interestingly, the introduction of WT D133p53b in the poorly invasive WT TP53 MCF7 breast can-
cer cells that express all WT p53 isoforms but D133p53b, enhances MCF7 invasive activity. In WT
TP53 HCT116 colon cancer cells, that express all WT p53 protein isoform including low level of
D133p53b protein, we demonstrated that HCT116 invasive activity can be controlled (enhanced or
inhibited) by siRNAs specific of different p53 isoforms to modulate expression of different subsets of
p53 protein isoforms. Hence HCT116 invasive activity is inhibited after depletion of D133p53 or b
isoforms by siRNA si133 or sib respectively while HCT116 invasive activity is enhanced after deple-
tion of WT full-length p53 proteins (TAp53a, TAp53b, TAp53g, D40p53a, D40p53b and D40p53g) by
siRNA siTA. Furthermore, ectopic expression of WT D133p53b in HCT116 cells enhances their inva-
sive activity.
Altogether, D133p53b expression provides a rationale for invasive cancers expressing WT TP53
and non-invasive cancers expressing missense mutant TP53. These data suggest that epigenetic
mechanisms that stem D133p53b expression, i.e. alternative splicing and induction of the TP53 inter-
nal promoter favour cancer invasion and dissemination of metastatic cells, regardless of TP53 muta-
tion status. Our data indicate that all three D133p53 isoforms (D133p53a, D133p53b and D133p53b)
promote invasion. This is in accordance with recent reports showing that D133p53a stimulate angio-
genesis and cell invasion (Bernard et al., 2013; Roth et al., 2016). Here we identified the D133p53b
isoform as being the most efficient promoter of invasion, corroborating its role as a predictive indi-
cator of cancer relapse and death in the clinic.
We investigated then how D133p53b regulate cell invasion in cancer cell lines. Since EMT leads to
profound phenotypic changes due to genome-scale epigenetic reprogramming and post-transcrip-
tional regulation, we studied the regulation of EMT by D133p53b to illustrate a molecular mechanism
of D133p53b. Our data indicate that expression of D133p53b promotes acquisition of a rounded-
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blebbing movement, which is associated with decrease of E-cadherin and b1-integrin in colon cancer
HCT116 cells. These phenotypic changes are hallmarks of epithelial-amoeboid transition (EAT), a
derivative of EMT which produces highly invasive cells. Depletion of D133p53 isoforms also induces
E-Cadherin expression and concomitantly inhibits Vimentin expression in invasive breast cancer
MDA-MB-231 D3H2LN cells. Accordingly, knockdown of D133p53 isoforms in colon cancer LoVo
cells decreased 3-D cell scattering, a process associated with EMT/EAT. Our study supports a critical
role for D133p53b (whether WT or mutant) in the induction of cell invasion and EMT/EAT.
In summary, our data lead us to conclude that the biological activities associated with WT or
mutant TP53 gene expression are not carried out by the single full-length p53 protein (TAp53a). p53
isoforms underlie the dual role of WT TP53 gene in preventing or promoting cancer cell invasion.
The invasive activities of cancer cells expressing WT or mutant TP53 gene can be enhanced or inhib-
ited by respectively increasing or reducing expression of D133p53b (Figure 5G). Testing the prog-
nostic discriminatory potential of D133p53b could influence clinical practice and may offer
appropriate and yet unexplored therapeutic options for mutant or WT TP53 tumors expressing
D133p53b.
Materials and methods
Breast cancer patients
Primary, previously untreated and operable breast cancers from 273 Caucasian women, with suffi-
cient tumor tissue surplus to diagnostic requirements and with complete clinical and pathological
data, were analyzed. To minimize variations such as different surgical techniques and skills, which
would have an effect on the rates of cancer recurrence and death, all tumors were provided by only
one surgeon, Prof Alastair Thompson, breast cancer surgeon at Ninewells hospital in Dundee. More-
over, all patients were treated at Ninewells Hospital according to established clinical protocols. Fur-
thermore, to minimize variation in tumor handling, all tumors were collected, stored, processed,
extracted and stained by the Tayside Tissue Bank according to validated and standardized protocols
at Ninewells Hospital. RNA quality was assessed using the BioAnalyzer 2100 prior to RT-PCR analysis
and all samples with a ratio of 28S/18S < 1.2 were discarded. In addition, the Tayside Tissue Bank
collected and verified the clinico-pathological data established by two anatomo-pathologists. Fur-
thermore Tayside Tissue Bank collected and anonymised all the clinical data (treatment, patient fol-
low-up).
The median age at diagnosis of the breast cancer patient cohort was 61.5 years (range 28.7 to
89.1 years) and median follow-up period was 6.85 years (range 0.29 to 13.7 years). Tumor tissues
were macro-dissected by a specialist breast pathologist and snap frozen in liquid nitrogen prior to
storage at  80ºC. The samples were examined following Local Research Ethics Committee approval
under delegated authority by the Tayside Tissue Bank (www.taysidetissuebank.org).
Tumor grade, estrogen receptor, progesterone receptor and HER2
status
Immunohistochemical staining was carried out on 4 mm sections of formalin-fixed paraffin-embedded
tumors, as previously described (Purdie et al., 2010).
RT-PCR and p53 mutation analysis
To generate cDNA from tumor total RNA extracts, two independent reverse transcription of 300 ng
of total RNA were performed and pooled (Khoury et al., 2013). The quality of the reverse Transcrip-
tion (cDNA) was assessed by quantification of the Actin and p53 cDNAs using quantitative Real-
Time PCR (Sybr Green) previously described (Khoury et al., 2013). All cDNA samples for which
Actin or p53 cDNA could not be detected in less than 30 cycles were discarded as it indicates that
the reverse-transcription did not work properly. This step reduces the number of false-negative sam-
ples that would bias the statistical analysis.
The sensitivity and specificity of the RT-PCR analysis were improved by performing 2 successive
PCR of 35 cycles each and by using 2 sets of nested primers for each D133p53 mRNA variants.
Therefore the RT-PCR analysis specifically amplifies D133p53a, D133p53b or D133p53g mRNA. The
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primer sequences are provided in Table 1 and a detailed protocol is described in the ’extended
experimental procedures’.
In the first PCR of 35 cycles, all D133p53 mRNA variants were amplified using a forward primer
corresponding to the 5’UTR of the D133p53 mRNA (TP53 intron-4) and a reverse primer correspond-
ing to the exon-10. Then, the product of the first PCR (1ul) is re-amplified in the second PCR of 35
cycles using a nested forward primer located in the 5’UTR of the D133p53 mRNA (intron4) and a
nested reverse primer spanning the exon junction between exon-9 and exon-10 to specifically
amplify the DD133p53a cDNA. To specifically amplify the D133p53b cDNA, the product of the first
PCR (1ul) is re-amplified in the second PCR of 35 cycles using the nested forward primer located in
the 5’UTR of the D133p53 mRNA (intron4) and a nested reverse primer corresponding to the exon9b
encoding the b C-terminal amino-acid sequence. To specifically amplify the D133p53g cDNA, the
product of the first PCR (1ul) is re-amplified in the second PCR of 35 cycles using the nested forward
primer located in the 5’UTR of the D133p53 mRNA (intron4) and a nested reverse primer spanning
the exon junction between exon-9 and exon-9g that encodes the g-C-terminal amino-acid sequence.
The RT-PCR analysis was tested in p53-null cells (H1299) and on a panel of cell lines expressing TP53
gene (MCF7, MDA-MB-231, HCT116). The products of the second PCR were then validated by
sequencing and after electrophoresis on 1% agarose gel.
For the RT-PCR analysis of the tumor samples, the products of the second PCRs were validated
for all tumors by electrophoresis on 1% agarose gel. The PCR products of at least 2 tumor samples
were sequenced to validate identity of the amplified D133p53 mRNA variants. The samples giving
rise to a PCR product of the expected size were deemed positive for the expression of the corre-
sponding D133p53 mRNA variant otherwise they were deemed negative. The two successive PCR of
35 cycles using two nested sets of primer maximize sensitivity and specificity of amplification. It ena-
bles to detect and identify the expression of each D133p53 variants even if expressed in a small pop-
ulation of tumor cells, taking account thus of tumor cell heterogeneity. It allows thus to compare
their expression and respective association with the clinico-pathological markers and/or patient clini-
cal outcome. The expression of p53 isoforms and analysis of p53 mutation were performed as
described in the extended experimental procedures.
Statistical analysis
The statistical clinical analysis was performed as described previously (Bourdon et al., 2011). All sta-
tistical comparisons were made using Wilcoxon test and a p-value < 0.05 was considered to be sta-
tistically significant.
DNA constructs, reagents and antibodies
Human p53 isoform constructs (Bourdon et al., 2005) were sub-cloned into pEGFPC1 (Clontech) or
pLPCmyc. Antibodies were purchased from BD-transduction laboratories, Santa Cruz and GE-
Healthcare. Dilutions are indicated in extended experimental procedures.
Cell culture, transfections and adhesion assay
Cells were cultured at 37˚C in the presence of 5% CO2 in McCOY’5A or DMEM media (Sigma) for
colon cancer and breast cancer cells, respectively. HCT116 (RRID:CVCL-0291), MDA-MB231 (RRID:
CVCL-0062), MCF7 (RRID:CVCL-0031), LoVo (RRID:CVCL-0399), SW480 (RRID:CVCL-0546), SW620
(RRID:CVCL-0547), Colo205 (RRID:CVCL-0218) were purchased from ATCC. MDA-MB231 D3H2LN
(RRID:CVCL-D257) were purchased from PerkinElmer. All cell lines were tested for mycoplasma con-
tamination after thawing using Lonza mycoalert assay (Reference number: LT27-236). Transfections
of p53 isoforms and siRNA were carried out using JetPEI kit (Qbiogen) and Interferin (Polyplus),
respectively, according to the manufacturers’ instructions. For adhesion assays, non-adherent and
adherent cells were collected 24 hr after transfection and counted using the Countess cell counting
system (Invitrogen).
Time-lapse imaging
Time-lapse DIC microscopy was performed on a Leica DMIRE2 inverted microscope with an auto-
matic shutter and GFP filter sets, as described in the extended experimental procedures.
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Cell extracts, western blotting
Non-adherent and adherent cell extracts were obtained and analyzed by western blotting. Detailed
protocols are described in the extended experimental procedures. Cells were lysed and protein
complexes were co-immunoprecipitated using GFP-Trap beads (Chromotek) as previously described
(Arsic et al., 2012). Sources of antibodies are provided in the extended experimental procedures.
Migration and invasion assays
Colon cancer cell migration and invasion were performed using Boyden chambers (Vinot et al.,
2008). Breast cancer cell invasion assays were performed as previously described (Smith et al.,
2008).
Quantitative Real-Time PCR (RT-qPCR or Taqman)
Total RNA was extracted with the RNeasy Mini Kit (Qiagen) and treated with DNase (Qiagen) prior
to reverse transcription, which was carried out using oligo(dT) (Invitrogen) and M-MLV reverse tran-
scriptase (Invitrogen). Sub-classes of p53 mRNA isoforms were quantified by Real-Time PCR (Taq-
Man) as previously described (Aoubala et al., 2011; Moore et al., 2010). All measurements were
normalized to the expression of the TATA box-binding protein (TBP) gene.
Extended experimental procedures
Tumor grade, estrogen receptor, progesterone receptor and HER2 status
Immunohistochemical staining was carried out on 4 mm sections of formalin-fixed paraffin-embedded
tumors with the mouse monoclonal anti-estrogen receptor alpha (ER) antibody 6F11 (Novocastra
Laboratories Ltd), progesterone receptor (PR) antibody clone 16, (Novocastra Laboratories Ltd) and
mouse monoclonal anti-HER2 antibody CB11 (Novocastra Laboratories Ltd). Additional analyses
were performed according to histological tumor grade (Bloom and Richardson, 1957) and graded
by a specialist consultant breast pathologist. ER status (as ER negative 0–3 versus ER positive 4–18)
was determined by the Quickscore method (Detre et al., 1995). HER2 scoring was performed as
previously described (Purdie et al.,2010).
RT-PCR analysis
Approximately 10 mg of tumor tissue (>40% of tumor cells) was homogenized in 750 ml QIAzol lysis
reagent (Qiagen Ltd, Crawley, West Sussex, UK) and total RNA was extracted (Qiagen). RNA quality
was assessed using the BioAnalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA), prior to RT-
PCR analysis and all samples with a ratio of 28S/18S < 1.2 were discarded. To generate cDNA from
tumor total RNA extracts, two independent reverse transcription of 300ng of total RNA were per-
formed using the Cloned AMV Reverse Transcription kit (Invitrogen) following manufacturer recom-
mendation (Khoury et al., 2013). The quality of the reverse Transcription (cDNA) was assessed by
quantification of the Actin and p53 cDNAs using quantitative Real-Time PCR (Sybr Green) previously
described. Primers are provided in Table 1 (Khoury et al., 2013). All cDNA samples for which Actin
or p53 cDNA could not be detected in less than 30 cycles were discarded. In the first PCR of 35
cycles, all D133p53 mRNA variants were amplified using a forward primer corresponding to the
5’UTR of the D133p53 mRNA (TP53 intron-4) and a reverse primer corresponding to the exon-10.
Per reaction mix (1 sample): 5x Green buffer Go Tag (Promega): 10 ml; dNTP (10 mM): 1 ml; forward
Primer (10 uM): 1 ul; reverse Primer (10 mM) 1 ml; Go Taq DNA (Promega) 0.25 ml; 2 ml of cDNA com-
plete at 50 ml final volume with milliQ water.Thermal cycling conditions for PCR amplification (1st
PCR reactions) for p53 isoforms are as follows: [94˚C for 3 min (1 cycle)], [94˚C for 30 s, 63˚C for 30 s,
72˚C for 1 min 30 s (35 cycles)] and finally [72˚C for 8 min (1 cycle)].
Then, the product of the first PCR (1ul) is re-amplified in the second PCR of 35 cycles using a
nested forward primer located in the 5’UTR of the D133p53 mRNA (intron4) and a nested reverse
primer spanning the exon junction between exon-9 and exon-10 to specifically amplify the
D133p53a cDNA. To specifically amplify the D133p53b cDNA, the product of the first PCR (1 ul) is
re-amplified in the second PCR of 35 cycles using the nested forward primer located in the 5’UTR of
the D133p53 mRNA (intron4) and a nested reverse primer corresponding to the exon-9b encoding
the b C-terminal amino-acid sequence. To specifically amplify the D133p53g cDNA, the product of
the first PCR (1ul) is re-amplified in the second PCR of 35 cycles using the nested forward primer
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located in the 5’UTR of the D133p53 mRNA (intron4) and a nested reverse primer spanning the exon
junction between exon-9 and exon-9g that encodes the g-C-terminal amino-acid sequence. Per reac-
tion mix (1 sample) : 10 ml; dNTP (10 mM): 1 ml; forward Primer (10 uM): 1ul; reverse Primer (10 mM)
1 ml; Go Taq DNA (Promega) 0.25 ml; Add 1 ml of c-DNA from1st PCR; complete at 50 ml final volume
with milliQ water. Thermal cycling conditions for PCR amplification (2nd PCR reactions): [94˚C for
3 min (1 cycle)], [94˚C for 30 s, 60˚C for 45 s, 72˚C for 1 min 30 s (35 cycles)] and finally [72˚C for
8 min (1 cycle)].
The PCR products are then analyzed by electrophoresis on 1% agarose gel. The RT-PCR analysis
was tested in p53-null cells (H1299) and on a panel of cell lines expressing TP53 gene (MCF7, MDA-
MB-231, HCT116). The products of the second PCRs were validated for all tumors by electrophoresis
on 1% agarose gel. The PCR products of at least 2 tumor samples were sequenced to validate iden-
tity of the amplified D133p53 mRNA variants.
TP53 mutation analysis
TP53 mutation status was determined from p53 PCR fragment as previously described
(Bourdon et al., 2005).
Statistical analysis
The primary outcomes in this study were breast cancer-specific overall survival (abbreviated to over-
all survival) and breast cancer-specific disease-free survival (abbreviated to disease-free survival or
cancer recurrence throughout the text), and accordingly, non-breast cancer deaths were censored at
the time of death (i.e. at the time of their death, the women were considered to have survived breast
cancer but died of other causes).
DNA constructs, reagents and antibodies
The human p53 isoform constructs used in this report were previously described (Bourdon et al.,
2005). They were sub-cloned into the EcoRI and BamHI sites of pEGFPC1 (Clonetech) to obtain
GFP-tagged proteins or in the BamHI and EcoRI sites of pLPCmyc to obtain myc-tagged proteins.
Constructs were amplified using the Nucleobond PC 500 kit (Macherey-Nagel) according to the
manufacturer’s instructions. Human D133p53 isoforms (a, b and g) were cloned into pMSCVhyg
(Clontech Laboratories) plasmid for retrovirus production. pSIREN-Luc (luciferase)-shRNA was pur-
chased from Clontech. The mouse anti-E-Cadherin (clone 36) and the mouse anti-Beta1-Integrin,
were purchased from BD-transduction laboratories and were diluted at 1/400˚ and 1/250˚, respec-
tively. The mouse N-Cadherin (clone 32/BD Transduction laboratories), and the rabbit polyclonal
anti-GFP (Invitrogen, Life Technologies, A-6455) were used at 1/400˚, 1/250˚, 1/300˚ and 1/2000˚,
respectively.
The sheep pantropic p53 antibody Sapu was diluted at 1/5000˚. The rabbit polyclonal KJC8 anti-
body specific of the b p53 isoforms was diluted at 1/4000˚ (Bourdon et al., 2005). The Horse-Radish
Peroxidase (HRP)-conjugated anti-IgG antibodies were purchased from GE-Healthcare and were
diluted at 1/5000˚. The Western Lightning Chemiluminescence (ECL) reagents were purchased from
PerkinElmer.
Time-lapse imaging
Time-lapse DIC microscopy was performed with a 63x oil-immersion objective (HC x PL APO 1.32–
0.6 oil CS), sample heater (37˚C) and homemade CO2 incubation chamber. Images were captured
with micromax CCD camera (1300Y/HS) imaging software, converted into TIFF files and edited and
compiled with Metamorph software. The exposure time was 500 ms for GFP and 300 ms for light.
Images were captured every 3 sand during 5 min or every 4 min during 12 hr.
Cell extracts, western blotting
Media containing blebbing cells was spun down at 1200 rpm for 5 min and the pellet constituted of
blebbing invasive cells was lysed. The remaining adherent cells were gently scraped in lysis buffer.
The two populations of cells were analyzed separately for each condition (see Figure legends). Total
protein concentration was determined using the BCA kit (Promega). Protein samples were electro-
phoretically separated on 8% SDS-PAGE gels for E-Cadherin and Beta1-Integrin. An equal amount
Gadea et al. eLife 2016;5:e14734. DOI: 10.7554/eLife.14734 22 of 26
Research article Cancer Biology
of total protein (30 mg) was loaded into each lane. Proteins were then transferred onto nitrocellulose
membranes. Membranes were blocked with TBS/0,1% Tween 20 containing 3% milk for one hour
and then incubated overnight with the primary antibodies diluted in TBS/0,1% Tween 20 containing
3% milk. After several washes in TBS/Tween, membranes were incubated with anti-rabbit or anti-
mouse Ig antibodies linked to HRP. Membranes were developed with ECL according to the manu-
facturer’s instructions. All scanned autoradiographs were quantified using AIDA/2D densitometry
software.
Western blotting analysis of tissue samples
Tissues were dissected and snap frozen in liquid nitrogen. Tissue chunks were placed in
an Eppendorf tube containing RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and
PBS, pH: 7.4, supplemented with protease inhibitor Complete (Roche) and iron beads. Tubes were
then placed in Qiagen Retsch MM 300 tissue lyser and shook 4 times for 45 s (frequence 20). Sam-
ples were then centrifuged at 12000RPM for 10 min at 4C. Pellets were discarded and supernatants
were sonicated (20 s, 30% amplitude). Protein concentration was determined using BCA Protein
Assay Kit (Thermo Scientific). Protein extracts were then analyzed by SDS-PAGE as described (20 ug
protein extract were loaded per well). Actin was used as a loading control. The rabbit polyclonal
antibody KJC8 specific of the beta p53 isoforms was diluted at 1 mg/ml in 4.5% milk in PBS/Tween
and incubated overnight at 4C.
Migration and invasion assays in Boyden chambers
The quantification of cell invasion was carried out in Transwell cell culture chambers containing fluo-
rescence-blocking polycarbonate porous membrane inserts (Fluoroblock; #351152; BD Biosciences;
pore size 8 mm). 100 ml of 1 mg/mL Matrigel with reduced growth factors (a commercially prepared
reconstituted BM from Englebreth-Holm-Swarm tumors, # 354230; BD Biosciences) were prepared
in a Transwell. Cells were transfected as monolayers before trypsinization and plating in 2% FCS-con-
taining media on top of a thick layer (around 500 mm) of Matrigel contained within the upper cham-
ber of a Transwell. Controls were left untreated. The upper and lower chambers were then filled
with, respectively, 2% FCS- containing media and media with 10% FCS, thus establishing a soluble
gradient of chemo-attractant that permits cell invasion throughout the Matrigel. Cells were allowed
to invade at 37˚C, 5% CO2 through the gel before fixing for 15 min in 3.7% formaldehyde. Cells that
had invaded through the Matrigel were detected on the lower side of the filter by GFP fluorescence
and counted. Six fields of the filter were counted and each assay was performed at least three times
in triplicate for each condition.
FACS analysis
Cells were transfected with the GFP-tagged isoforms of p53, harvested 24 hr after transfection and
then spun down at 1200 rpm for 5 min and fixed by adding 1 mL of 70% EtOH at  20˚C. For each
condition, propidium iodide staining was performed and the number of GFP-expressing cells was
compared to total cells after quantification by FACS analysis using the CellQuest software.
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